Kiniksa Pharmaceuticals International, plc $KNSA Stake Raised by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company boosted its holdings in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 56.7% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 63,346 shares of the company’s stock after acquiring an additional 22,917 shares during the quarter. The Manufacturers Life Insurance Company owned 0.08% of Kiniksa Pharmaceuticals International worth $3,050,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. KBC Group NV acquired a new position in shares of Kiniksa Pharmaceuticals International in the 1st quarter valued at about $34,000. Smartleaf Asset Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International during the fourth quarter worth approximately $36,000. EverSource Wealth Advisors LLC grew its position in Kiniksa Pharmaceuticals International by 140.4% during the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after purchasing an additional 532 shares in the last quarter. Nano Cap New Millennium Growth Fund L P purchased a new position in Kiniksa Pharmaceuticals International during the fourth quarter valued at approximately $41,000. Finally, CIBC Private Wealth Group LLC acquired a new position in Kiniksa Pharmaceuticals International in the 4th quarter valued at approximately $41,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Insider Transactions at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, Director G Bradley Cole sold 3,673 shares of the company’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $81.43, for a total transaction of $299,092.39. Following the completion of the sale, the director directly owned 11,672 shares in the company, valued at $950,450.96. This represents a 23.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 51.98% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

KNSA has been the subject of a number of research analyst reports. JPMorgan Chase & Co. increased their target price on shares of Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 12th. Canaccord Genuity Group increased their price objective on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Weiss Ratings raised Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, July 29th. Finally, Zacks Research downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 30th. Nine research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $87.38.

Kiniksa Pharmaceuticals International Stock Down 0.6%

Shares of KNSA stock opened at $76.06 on Friday. Kiniksa Pharmaceuticals International, plc has a 12 month low of $31.78 and a 12 month high of $82.94. The company has a market cap of $5.85 billion, a PE ratio of 78.41 and a beta of 0.05. The business’s 50 day moving average is $61.50 and its two-hundred day moving average is $52.41.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, July 28th. The company reported $0.30 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.30. The business had revenue of $243.60 million during the quarter, compared to the consensus estimate of $226.49 million. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. As a group, equities analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.37 EPS for the current fiscal year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.